345 related articles for article (PubMed ID: 11242605)
21. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.
Gross JL; Kramer CK; Leitão CB; Hawkins N; Viana LV; Schaan BD; Pinto LC; Rodrigues TC; Azevedo MJ;
Ann Intern Med; 2011 May; 154(10):672-9. PubMed ID: 21576535
[TBL] [Abstract][Full Text] [Related]
22. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
23. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975
[TBL] [Abstract][Full Text] [Related]
24. Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes.
Vos RC; Rutten GEHM
JAMA; 2017 Oct; 318(15):1489-1490. PubMed ID: 29049639
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
Hung AM; Roumie CL; Greevy RA; Grijalva CG; Liu X; Murff HJ; Ikizler TA; Griffin MR
Clin J Am Soc Nephrol; 2016 Dec; 11(12):2177-2185. PubMed ID: 27827311
[TBL] [Abstract][Full Text] [Related]
26. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura E; Hosaka D; Imai Y; Kawazu S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
[No Abstract] [Full Text] [Related]
27. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
Bayraktar M; Van Thiel DH; Adalar N
Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
[TBL] [Abstract][Full Text] [Related]
28. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
29. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
Goldstein BJ; Pans M; Rubin CJ
Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
[TBL] [Abstract][Full Text] [Related]
30. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
[TBL] [Abstract][Full Text] [Related]
31. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
32. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
Abdul-Ghani M; Migahid O; Megahed A; Adams J; Triplitt C; DeFronzo RA; Zirie M; Jayyousi A
Diabetes Care; 2017 Mar; 40(3):325-331. PubMed ID: 28096223
[TBL] [Abstract][Full Text] [Related]
33. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
[TBL] [Abstract][Full Text] [Related]
34. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A; Lipetz R; Wu J; Schwartz S
Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin.
Pareek A; Chandurkar NB; Salkar HR; Borkar MS; Tiwari D
Am J Ther; 2013 Jan; 20(1):41-7. PubMed ID: 21326082
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?
Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R
J Endocrinol Invest; 1998 Dec; 21(11):744-7. PubMed ID: 9972673
[TBL] [Abstract][Full Text] [Related]
39. [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Hanefeld M; Fischer S
MMW Fortschr Med; 2003 Feb; 145(9):30-4. PubMed ID: 12666526
[TBL] [Abstract][Full Text] [Related]
40. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
Schernthaner G; Rosas-Guzmán J; Dotta F; Guerci B; Simó R; Festa A; Kiljański J; Zhou M; Gallwitz B
Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
